FLSC

10.0800.10%
KL

Kevin Li

Chief Business Officer

Mr. Kevin Li, M.D., is a Director of Angitia Biopharmaceuticals Guangzhou Limited since February 2026. He is Partner of Frazier Life Sciences Management, LP. He was Principal of Frazier Life Sciences Management, LP. He was Vice President of Frazier Life Sciences Management, LP. He is Principal of Frazier Management, L.L.C. from 2024. He joined the Frazier Management, L.L.C. in 2021. He focuses on life science. He was Vice President of Frazier Management, L.L.C. from 2022 to 2024. He was Senior Associate of Frazier Management, L.L.C. from 2021 to 2022. He is a part of the Frazier Life Sciences Investment team focused on identifying and evaluating new investment opportunities in public companies. He focuses on identifying and evaluating new public investment opportunities. He was previously a physician in Internal Medicine at Stanford, where he cared for patients at Stanford University Medical Center and affiliated clinics. He has published over 15 peer-reviewed research articles on healthcare outcomes and utilization, clinical informatics and quantitative pathology. During medical school, he also worked in life sciences investing as a summer associate at Frazier and at Acuta Capital. Before his medical training, he was a consultant at McKinsey and Company, where he worked with clients in the hospital services and pharmaceutical industries on corporate strategy, growth and mergers and acquisitions. He received his M.D. from Stanford University and his B.S. from Yale University, where he graduated summa cum laude in Molecular Biophysics and Biochemistry and was a member of Phi Beta Kappa. Mr. Li is Chief Business Officer of Frazier Life Sciences Acquisition Corp II from August 2026. Mr. Li joined the Frazier Life Sciences Acquisition Corp II in August 2026.

Positions